Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04074837
Recruitment Status : Recruiting
First Posted : August 30, 2019
Last Update Posted : May 6, 2020
Sponsor:
Collaborator:
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Neuronascent, Inc.

Brief Summary:
The purpose of this study is to examine the safety, tolerability and pharmacokinetics of single and multiple doses of NNI-362 in healthy aged population.

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: NNI-362 Drug: Placebo Phase 1

Detailed Description:
The early clinical development strategy consists of the initial evaluation of safety and tolerability of NNI-362. This FIH Phase I includes single and multiple ascending dose studies in healthy aged volunteers. Assessment of suicidal ideation/behavior will be performed at baseline and at all study visits and on days of inpatient confinement in conformance with FDA recommendations.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Placebo versus NNI-362 at 10 mg, 20 mg, 60 and 120 mg liquid suspension
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Quadruple (Participant, Care Provider, Investigator, Outcome Assessor)
Primary Purpose: Treatment
Official Title: Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age
Actual Study Start Date : August 1, 2019
Estimated Primary Completion Date : October 1, 2020
Estimated Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo liquid suspension.
Drug: Placebo
Placebo liquid suspension

Active Comparator: NNI-362, 10 mg
NNI-362 at 10 mg in liquid suspension
Drug: NNI-362
NNI-362 small molecule in liquid suspension.

Active Comparator: NNI-362, 20 mg
NNI-362 at 20 mg in liquid suspension
Drug: NNI-362
NNI-362 small molecule in liquid suspension.

Active Comparator: NNI-362, 60 mg
NNI-362 at 60 mg in liquid suspension
Drug: NNI-362
NNI-362 small molecule in liquid suspension.

Active Comparator: NNI-362, 120 mg
NNI-362 at 120 mg in liquid suspension
Drug: NNI-362
NNI-362 small molecule in liquid suspension.




Primary Outcome Measures :
  1. Measure number of treatment related adverse events following single and multiple dosing of NNI-362. [ Time Frame: 5 to 15 days ]
    To examine the number of participants with treatment-related adverse events according to criteria of CTCAE v4.0


Secondary Outcome Measures :
  1. Measure Maximum Plasma Concentration with single or multiple dosing of NNI-362. [ Time Frame: 48 hours ]
    Following single and multiple dosing of oral NNI-362 assess the maximum plasma concentration [Cmax].

  2. Measure Area Under the Curve with single and multiple dosing of NNI-362 [ Time Frame: 48 hours ]
    Following single and multiple dosing of oral NNI-362 assess the area under the curve [AUC].



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 72 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy aged volunteers of either sex between the ages of 50 and 72 inclusive at time of screening.

    • Subjects must be in reasonably good health as determined by investigator based on medical history, vital signs measurements, physical examination, screening laboratory results and ECG.
    • Normal age-related findings as well as well-controlled, chronic and stable medical conditions (e.g., hypertension, osteoarthritis, non-insulin dependent diabetes mellitus, osteoporosis, gout, Paget's disease, hypothyroidism) will not be exclusionary if they are not expected to compromise subject safety, study conduct, or study objectives.
    • Non-interacting medications for stable allowable medical conditions will be allowed following review and approval by the medical monitor.
    • An adequate understanding of the requirements of the study, provision of written informed consent, and agreement to abide by the study restrictions.
    • Negative urine screen for drugs of abuse within 24 h before the administration of the first dose of study drug and in the multiple dose study upon readmission to the clinical unit from outpatient status.
    • Body Mass Index (BMI) of between 18 and 30 kg/m2 inclusive, and a total body weight greater than 48kg at screening.

Exclusion Criteria:

  • • Women of child-bearing potential, defined as premenopausal (unless the potential research subject has previously undergone hysterectomy and/or bilateral salpingo-oophorectomy)

    • Pregnant or breastfeeding
    • Any clinically significant hematology, chemistry, coagulation, or urinalysis value at screening and day -1 Abnormal liver enzymes (ALT and/or AST >1.5X ULN) at screening and day -1
    • Serum creatinine > ULN at screening and day -1
    • Hemoglobin <13 g/dL for males or <11.5 g/dL for females, leukocytes <3.0 X 103/uL, absolute neutrophil count <1000/uL, or platelets <150 X 103/uL at screening and day -1
    • Any significant medical illness that could compromise the interpretability of study data or affect subject safety including, but not necessarily limited to:

      • Chronic pulmonary disease or sleep apnea
      • Clinically significant cardiac arrhythmia (either at screening or based on history)
      • Congestive heart failure, valvular heart disease or ischemic heart disease
      • Pulmonary hypertension
      • Any disorder of the kidney or urinary tract
      • Active peptic ulcer disease, gastrointestinal bleeding, inflammatory bowel disease, chronic pancreatitis
      • Liver disease (excluding Gilbert's syndrome)
      • Any neurologic disorder other than chronic Bell's Palsy
      • History of malignancy that has not been cured or in complete remission for at least 10 years (excluding resected non-metastatic basal cell carcinoma)
      • History of seizure activity other than early childhood
      • Any traumatic brain injury in adulthood
    • Current smoker or nicotine user (quit less than 2 months)
    • Active substance abuse.
    • Glomerular filtration rate <50 mL/min based on Cockcroft-Gault calculation using ideal (lean) body weight or present weight.
    • Difficulty swallowing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04074837


Contacts
Layout table for location contacts
Contact: Parexel International 814-254-1600 study.losangeles@Parexel.com

Locations
Layout table for location information
United States, California
Parexel, International Recruiting
Glendale, California, United States, 91206
Contact: Parexel    814-254-1600    study.losangeles@parexel.com   
Sponsors and Collaborators
Neuronascent, Inc.
National Institute on Aging (NIA)
Layout table for additonal information
Responsible Party: Neuronascent, Inc.
ClinicalTrials.gov Identifier: NCT04074837    
Other Study ID Numbers: NNI-001
1R01AG056561-01A1 ( U.S. NIH Grant/Contract )
First Posted: August 30, 2019    Key Record Dates
Last Update Posted: May 6, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: This clinical trial will be available for peer-reviewed publication.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders